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Abstract 
 Breast cancer is the second leading cause of death among women in the 
United States. Among the different molecular sub-groups of breast cancer, the 
most invasive is Triple-Negative Breast Cancer (TNBC). TNBC has the worst 
prognosis, decreased overall survival rate and no targeted therapy available. 
On-going research is investigating new strategies and therapies for TNBC. 
Therefore, this study’s objective was to compare and contrast the effects of 
continuous low-dose of BIBR 1532, a novel analogue of BIBR1532 (GV6), 
Paclitaxel and Doxorubicin on breast cancer (MDA-MB 231) cells. Culture flasks 
(T-25) were seeded with approximately 5.0x105 cells/ml and supplemented with 
GV6 (n=4-8) or BIBR 1532 (n=4-8) or Doxorubicin (n=4-8) or Paclitaxel (n=4-8) 
or non-drug supplemented media (Control, n=4-8) for 21 days. Trypan Blue 
(Gibco) exclusion test was utilized to assess the viability of the cells. BIBR 1532, 
Doxorubicin and Paclitaxel reduced (P<0.05) proliferation of the cancer cells by 
approximately 20-35% by day 7 of treatment compared to the Control. By day 
21 of low-dose GV6, BIBR1532, Doxorubicin and Paclitaxel supplementation, 
the cell counts dropped to about 25% (P<0.05), 55% (P<0.05), 75% (P<0.05) 
and 50% (P<0.05) of Control, respectively. Our results indicate that continuous 
low dose anti-telomerase and chemotherapeutic drugs do inhibit breast cancer 
cell proliferation and merits further investigation. 
  
Introduction 
      In 2014, the United States will have an estimated 250,000 new cases of 
invasive breast cancer that accounts for 14% of all new cancer cases (1). Of the 
250,000 new cases diagnosed in 2014, it is estimated that 40,000 will die due to 
the disease, which accounts for about 7% of all cancer-related deaths (1). In 
2012 there were 1.7 million new cases of breast cancer worldwide that cost 
about $88 billion in health care (1). This number represented about 12% of all 
new cancer cases and 25% of all cancers in women (9).  
 Breast cancers are currently classified into subclasses based on their 
ultrastructural morphology. Among the most invasive, with high metastatic and 
recurrence rates, as well as one of the worst prognoses is triple negative breast 
cancer (TNBC). In the US, TNBC is occurring in higher rates in younger women 
	  
Grand Valley State University 
Effects of Chronic Low Dose Anti-Telomerase and                                                       
Chemotherapeutic Drugs on Breast Cancer Cells 
2	  	  
and in African American women. The currently available drugs targeting other 
subtypes that over express the estrogen receptor or progesterone receptor or 
human epidermal growth factor receptor two (HER2) are of limited benefit with 
TNBC. This type of cancer over time can become very aggressive and difficult to 
treat.  Due to the aggressive nature of TNBC, a higher dose of chemotherapy 
and/or radiation is recommended to the patient. Studies have reported that 
patients show a variety of adverse side effects with higher doses ranging from: 
infertility, organ damage, secondary cancers, and fatality (1, 5, 6). For example, 
when high dose of cyclophosphamide (180 mg/kg) is administered, 28% of 
these patients start to show progressive signs of congestive heart failure, and 
19% of these patients succumb due to cardiac failure (4).   
 Recent developments in life sciences are providing new understanding to 
the cellular and molecular flaws of cancer cells. One field of study, being 
pursued by cancer researchers is the regulation of cellular replication. The two 
important elements of cellular replication are; division of the cytoplasm and the 
duplication of DNA. The main focus of the scientist has been on DNA 
replication, as it is part of the cell that encodes for all processes within the cell, 
and is passed from one cell to another during cell division. Cancer emanates 
when there is a flaw within one of the phases associated with DNA duplication, 
therefore making the cancer cells divergent from normal cells. Cytoplasmic 
replication has a limited role to play in triggering cancer because it is mostly 
involved in transportation of intracellular components. 
  During DNA replication, the cell proceeds through an inherent systemic 
quality control process via checkpoints, which detect alterations within the DNA. 
The damage can be induced by the environment, chemicals or genetics. 
Damaged or mutated cells cannot pass these checkpoints and are directed 
towards senescence. These checkpoints are controlled by cyclins and if a cyclin 
is mutated, it will affect the overall quality control process. Consequently, cancer 
cells will be able to bypass these checkpoints with atypical cyclins without being 
eliminated. Once these cells evade the internal screening mechanism, they 
acquire unrestricted proliferative capacity leading to malignant cells (2). A 
number of drugs targeting enzymes associated with the DNA duplication cycle 
have been developed to halt progression of cancer cells. Among them is 
Doxorubicin (DOX) from the anthracycline family, which is routinely used as an 
anti-cancer drug. Doxorubicin inhibits enzymes, such as topoisomerase II that 
are associated with DNA duplication.  
 In most human cells, an enzyme called telomerase helps cap the end of 
chromosomal DNA (telomere), this activity is low and barely detectable. As the 
DNA is replicated, telomere DNA becomes shorter with each cell division. 
Ultimately, when the telomere becomes too short, the chromosomal DNA is not 
protected and can be easily degraded (2). Interestingly now in cancer cells, we 
know the telomerase is reactivated with each cell cycle, which lengthens the 
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telomere to detectable lengths, causing the damaged DNA to stabilize and pass 
through the cell division checkpoints (2). Further understanding, of the 
telomere/telomerase complex has lead to the creation of a now common drug 
called Azidothymidine (AZT). AZT was used extensively to treat HIV and AIDS 
by targeting the replication of viral DNA. The knowledge of the 
telomere/telomerase complex has lead to a development of other synthetic anti-
telomerase molecules, including BIBR1532 (3). BIBR 1532 blocks the limitless 
proliferative capacity of metastatic cancerous cells by impeding the progression 
of telomere/telomerase complex (2). A novel analogue of the BIBR1532, named 
GV-6, has been developed at Grand Valley State University.   
 To counteract the side effects of the high-dose of chemotherapy used to 
treat TNBC, a number of studies are investigating chronic low-dose therapies (5, 
8, 9). Low dose therapies have been very effective at reducing the cytotoxic 
effect of the chemotherapeutic agents (5, 8, 9). Overall, studies show that in a 
low-dose therapy, the agent still has a significant effect on the cancerous cells, 
such as tumor size, while demonstrating limited toxicity (5, 8, 9). A recent study 
has shown that when a weekly low-dose was given, 36% of patients had a 
progressive decrease in tumor sizes, while having a limited number of side 
effects (5). The goal of this study was to evaluate the effect of chronic low-dose 
mono-therapies (BIBR1532 or GV6 or DOX) compared to combination 
(DOX+BIBR1532 or DOX+GV6) treatment on the proliferation of commercially 
available TNBC (MDA-MB 231) cells.  
Materials & Methods 
 
Cell line 
Breast cancer cells (MDA-MB231) were cultured in 
RPMI (Life Technologies, NY) media 
supplemented with 10% fetal bovine serum 
(Innovative Research, MI) plus 100uL of 100X 
Anti-Anti (Life Technologies, NY) in an incubator 
set at 37 °C and 5% CO2. 
 
Treatment 
Cells were seeded at a density of 0.50x106 cells/ml 
(T25) and cultured for 72 hours in solvent-free 
RPMI media to allow cells to acclimatize to culture 
conditions. Thereafter, the media was switched to 
fresh RPMI media alone for Control (n=2-4) or 
media supplemented with 10µm GV6 (Fig 1), or 10µm BIBR1532 or 100nm DOX 
(Fig 1) or 100nm DOX+10µm GV6 or 100nm DOX+10µm BIBR1532 (n=4-6). 
 
 
 
Figure	  1:	  (a)	  Chemical	  structure	  of	  BIBR1532	  (R=COOH)	  and	  GV6	  (R=unknown).	  (b)	  Chemical	  structure	  of	  Doxorubicin	  	  
b 
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Viability Assessment 
At days 7, 14, and 21 of culture with or without treatments, relative cell densities 
were evaluated by using a hemocytometer and the live/dead ratios were 
calculated using the Trypan Blue Exclusion Test (Life Technologies, NY). The 
number of live/dead cells was estimated by counting and averaging the number 
of cells within a set of four defined grids using an inverted microscope (Leica IL; 
100X). 
 
Senescence Test 
A commercially available Senescence-Associated β-galactosidase (SA-βGal) 
Staining Kit (Cell Signaling Technology, MA) was used on day 21 to detect the 
cellular activity of β-galactosidase at an acidic pH. The average percentage of 
SA-βGal positive cells per treatment was estimated from three independently 
obtained micrographs using an inverted microscope (Olympus, PA; 100X) 
 
Statistical 
Statistical analyses were performed 
using the Student paired t-test. P < 
0.05 was considered significant. 
 
Results 
 
Dose Curve  
The dose response curves of BIBR 
1532, GV6, doxorubicin and paclitaxel 
are shown in Figures 2a and b. There 
was not a large difference in the EC50 
concentrations of BIBR1532 and GV6 
(201nM vs 152nM, respectively). 
Similarly, the EC50 for doxorubicin was 
comparable to that of paclitaxel (15µM 
vs 17µM).The correlation coefficient 
(R2) values for BIBR 1532, GV6, and 
doxorubicin, paclitaxel dose-response 
curves were 0.98 and 0.99, 
respectively.  
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Figure 2: The Dose-Response curves of DOX, 
Paclitaxel, BIBR1532 and GV6. Figure 3b DOX 
and paclitaxel dose curve is made up of 
concentrations from 10µM to 1nM. Figure 3a 
BIBR1532 and GV6 dose curve is made up of 
concentrations form 1mM to 1nM. The EC50 for 
DOX, PAC, BIBR1532 and GV6 is: 201nM, 
152nM, 15µM and 17µM, respectively. (R2 =0.98 
to 0.99)  	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Effects of Single and 
Combination Anti-
telomerase and 
Anthracycline therapy 
on MDA-MB 231 cells 
The Figures 3 and 4 
show the effects of 
single and combination 
of anti-telomerase (GV6 
or BIBR1532) and 
anthracycline 
(doxorubicin) therapy 
on viable MDA-MB 231 
cells for 7, 14 and 21 
days compared to 
Control.  
 
The effects of the 
combination of 
doxorubicin with either 
BIBR1532 or GV6 
revealed a significant 
effect (P<0.001) 
compared to single 
treatments. Both GV6 
and BIBR1532 depicted 
similar potencies when 
compared to control. 
The efficacy of the 
combination treatment 
increased with duration 
of culture (p<0.001).  
                       
Senescence Test  
No difference was noted between the number of active cells between single and 
combination treatments (Figure 5a). The number of senescent cells was more in 
single and combination treatments when compared to control (Figure 5b). The 
amount of dead cells did not change much between treatments (Figure 6).  
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Figure 3: Number of viable MDA-MB 231 cells in media supplemented with 
GV6 and DOX+GV6 at days 7, 14, and 21 as determined by Trypan-Blue 
exclusion test (n=4-6). Cells counts are expressed relative to Control. Data is 
shown as Mean ± SD; ac, and bd means are significantly different (p<0.001).  	  
Figure 4:Number of viable MDA-MB 231 cells in media supplemented with 
BIBR1532 and DOX+BIBR1532 at days 7, 14, and 21 as determined by 
Trypan-Blue exclusion test (n=4-6). Cells counts are expressed relative to 
Control. Data is shown as Mean ± SD; ab means are significantly different 
(p<0.001)	  
 b 
Vi
ab
le
 C
el
ls
 (P
er
ce
nt
 o
f C
on
tr
ol
) 
 a 
 b 
	  
Grand Valley State University 
Effects of Chronic Low Dose Anti-Telomerase and                                                       
Chemotherapeutic Drugs on Breast Cancer Cells 
6	  	  
Discussion  
 
 TNBC has one the worst 
prognosis because it is missing the 
key factors that typical breast cancer 
has (1). These key factors are the 
reason why TNBC has one of the 
poorest prognoses. With these 
factors missing TNBC has a more 
aggressive nature and is therefore 
harder to treat. There is no specified 
treatment for TNBC. The only current 
treatment for TNBC is either a high-
dose of chemotherapy or radiation. 
The high dose of these agents has 
adverse side effects that can lead to 
organ failure or even death (1,4,5,6). 
Without a specific target to use 
against TNBC, scientists have been 
looking for other factors which can be 
targeted to fight TNBC. A few of the 
factors they have found that can be 
targeted in TNBC cells are, the 
amount of telomere DNA and the cell 
checkpoints within the cell replication 
stages. One of the most common 
anthracycline is doxorubicin and the 
most common anti-telomerase 
agents is BIBR1532 and the novel 
GV6 (2,3).	    
 
 Doxorubicin is noted to be 
very effective against TNBC 
(5,6,7,8). A recent study has shown that it reduces tumor size significantly but is 
cytotoxic and cells do develop resistance (5,6,7,8). On other hand, BIBR1532 is 
also shown to be very effective against TNBC. A recent study showed that 
BIBR1532 worked very well against TNCB cells when glucose levels were 
increased (13). The single and combination of effects of chronic low dose of 
these chemotherapy drugs on MDA-MB 231 cells is the main target of this 
study.  
 
 To our knowledge, this is the first study that demonstrates effectiveness 
of BIBR1532 or GV6 in combination with DOX against TNBC in a chronic low-
dose regime. The steady decrease in the number of viable MBA-MB 231 cells 
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Figure	  5:	  Number	  of	  (A)	  non-­‐senescent	  (replicatively	  active)	  cells,	  and	  (B)	  senescent	  cell/treatment	  in	  comparison	  to	  Control	  on	  day	  21	  of	  treatment.	  Data	  is	  shown	  as	  Mean	  SD.	  ab,	  ad,	  af,	  ag,	  ah,	  and	  ai	  means	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  each	  panel	  are	  significantly	  different	  (p<0.05)	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indicates that the treatments of 
BIBR1532 or GV6 in combination with 
DOX are efficacious (figure 3 and 4). 
The results also show that the number 
of senescent cells in the combination 
trails have not increased when 
compared to the single treatments 
(figure 5). The amount of dead cells 
within the combination trails also has 
deceased slightly form the single 
treatment trails. The results of this 
experiment have shown that there is a 
significant difference between single 
and combination treatments.  
 
 The combination of the 
BIBR1532 or GV6 with DOX shows 
similar results (figure 3 and 4). Recent 
studies have shown that the combination of different drugs with DOX when used 
against TNBC has been more effective then single treatments with less cytotoxic 
effects (5,8,9,10). A recent study revealed that the combination of doxorubicin or 
paclitaxel with another anti-cancer or anti-telomerase drug is very effective 
against many different cell lines (12). These results are very comparable to the 
results shown here, presenting that both treatments works better in combination 
versus single treatment.  
 
 The dose curve for this trial showed an EC-50 of about 201nM for 
doxorubicin. Another study has shown an EC-50 of 130 nM for doxorubicin (11). 
This difference is plausibly from using two different cells lines and having slightly 
different culture conditions between the two studies (11). Additionally, our study 
found that the number of dead cells were generally higher in the single 
treatments versus the combination treatments.  
 
 This preliminary study illustrates that the combination of anti-telomerase 
with an anthracycline agents is more effective in inhibiting proliferation of TNBC 
when compared to both single-drug anti-telomerase mono-therapies. Further 
studies are necessary to verify and expand upon these current findings by next 
using patient derived cells. 
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